Education
About Us
Working with TipRanks
Follow Us
Altimmune (DE:3G0)
:3G0
3G0 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€5.02 - €10.12
Previous CloseN/A
Volume5.10K
Average Volume (3M)401.00
Market Cap
€371.43M
Enterprise Value€298.81M
Total Cash (Recent Filing)$36.93M
Total Debt (Recent Filing)$1.68M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
May 08, 2025EPS Estimate
-0.33Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding77,013,660
10 Day Avg. Volume261
30 Day Avg. Volume401
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)21005.48
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.94K
Enterprise Value/Ebitda-3.15
Forecast
1Y Price Target
€19.56Price Target Upside287.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPemvidutide's potential to meet dual primary endpoints of MASH resolution and fibrosis improvement positions it as a leading candidate in its field.
Financial PositionAltimmune is well-capitalized with $132M in cash, providing financial runway into the second half of 2026.
Bears Say
Market CompetitionCompetition is fierce in the obesity space, owing in large part to the success of the GLP-1 receptor drug class.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.96% Insiders
11.73% Mutual Funds
8.70% Other Institutional Investors
64.23% Public Companies and Individual Investors
3G0 FAQ
What was Altimmune’s price range in the past 12 months?
Altimmune lowest stock price was €5.02 and its highest was €10.12 in the past 12 months.
What is Altimmune’s market cap?
Altimmune’s market cap is €371.43M.
When is Altimmune’s upcoming earnings report date?
Altimmune’s upcoming earnings report date is May 08, 2025 which is in 57 days.
How were Altimmune’s earnings last quarter?
Altimmune released its earnings results on Feb 27, 2025. The company reported -€0.311 earnings per share for the quarter, beating the consensus estimate of -€0.313 by €0.002.
Is Altimmune overvalued?
According to Wall Street analysts Altimmune’s price is currently Undervalued.
Does Altimmune pay dividends?
Altimmune pays a Notavailable dividend of €822.588 which represents an annual dividend yield of N/A. See more information on Altimmune dividends here
What is Altimmune’s EPS estimate?
Altimmune’s EPS estimate is -0.33.
How many shares outstanding does Altimmune have?
Altimmune has 77,013,660 shares outstanding.
What happened to Altimmune’s price movement after its last earnings report?
Altimmune reported an EPS of -€0.311 in its last earnings report, beating expectations of -€0.313. Following the earnings report the stock price went down -3.91%.
Which hedge fund is a major shareholder of Altimmune?
Currently, no hedge funds are holding shares in DE:3G0
---
Altimmune Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.56 (287.28% Upside)
€19.56 (287.28% Upside)
Blogger Sentiment
Bullish
DE:3G0 Sentiment 70%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.70%
12-Months-Change
Fundamentals
Return on Equity
-59.86%
Trailing 12-Months
Asset Growth
-33.87%
Trailing 12-Months
Company Description
Altimmune
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
3G0 Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in Altimmune's pipeline with new INDs and a strong financial position. However, challenges such as increased expenses and a net loss, along with the retirement of a key executive, were noted.Read More>---
3G0 Stock 12 Month Forecast
Average Price Target
€19.56
▲(287.28% Upside)
Technical Analysis
Best Analysts Covering 3G0
1 Year
1 Year Success Rate
13/35 ratings generated profit
1 Year Average Return
+5.74%
reiterated a buy rating last month
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 45.71% of your transactions generating a profit, with an average return of +5.74% per trade.
---